Valeo Pharma CEO Steve Saviuk joined Steve Darling from Proactive to discuss the company's financial results for the first quarter ended January 31, 2024. Valeo Pharma reported revenues of $13.5 million in Q1-24, compared to $13.1 million in Q1-23 and $13.1 million in Q4-23, representing a 3% increase. The company recorded an adjusted gross profit of $3.9 million in Q1-24, similar to the figure in Q1-23, and a significant increase from $2.1 million in Q4-23, marking an 81% rise.
Saviuk told Proactive the number of prescribing physicians for Valeo Pharma's Enerzair and Atectura reached 3,472 by the end of Q1-24, reflecting a notable 17% growth for the quarter and a remarkable 119% increase year-over-year. Saviuk expressed confidence that Valeo Pharma's major promoted brands, including Enerzair, Simbrinza, and Redesca, will contribute increasingly to revenue growth in the upcoming quarters, accompanied by greater margin contribution. Valeo Pharma has initiated several measures aimed at achieving positive cash flow, with operational cost savings expected to have a more significant impact from Q2-24 onwards. These results indicate a positive trajectory for Valeo Pharma, driven by robust revenue performance, expanding physician adoption of key products, and strategic initiatives aimed at enhancing profitability and cash flow generation.